Hypoxia in prostate cancer: A powerful shield against tumour destruction?

Cancer Treatment Reviews

Volumn 34, Issue 4, 2008, Pages 313-327

  Marignol, L ^a,b   Coffey, M ^b   Lawler, M ^a,b   Hollywood, D ^a,b  

^a Academic Unit of Clinical and Molecular Oncology   (Ireland)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

HIF 1 ; Hypoxia; Prostate cancer; Radiation; ROS

Indexed keywords

ANDROGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; OXYGEN;

CYTOTOXICITY; HUMAN; HYPOXIA; OXIDATIVE STRESS; PROGNOSIS; PROSTATE CANCER; PROTECTION; REVIEW; TUMOR GROWTH;

ANDROGENS; APOPTOSIS; BIOLOGICAL MARKERS; CELL HYPOXIA; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MODELS, BIOLOGICAL; PROSTATIC NEOPLASMS; REACTIVE OXYGEN SPECIES;

EID: 44149092895     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2008.01.006     Document Type: Review

References (204)

1. Sivridis E., Giatromanolaki A., and Koukourakis M.I. The vascular network of tumours-what is it not for?. J Pathol 201 (2003) 173-180
2. Movsas B., Chapman J.D., Greenberg R.E., Hanlon A.L., Horwitz E.M., Pinover W.H., et al. Increasing levels of hypoxia in prostate carcinoma correlate significantly with increasing clinical stage and patient age: an Eppendorf pO(2) study. Cancer 89 (2000) 2018-2024
3. Movsas B., Chapman J.D., Hanlon A.L., Horwitz E.M., Greenberg R.E., Stobbe C., et al. Hypoxic prostate/muscle pO2 ratio predicts for biochemical failure in patients with prostate cancer: preliminary findings. Urology 60 (2002) 634-639
4. Pallares J., Rojo F., Iriarte J., Morote J., Armadans L.I., and de Torres I. Study of microvessel density and the expression of the angiogenic factors VEGF, bFGF and the receptors Flt-1 and FLK-1 in benign, premalignant and malignant prostate tissues. Histol Histopathol 21 (2006) 857-865
5. Bostwick D.G., and Iczkowski K.A. Microvessel density in prostate cancer: prognostic and therapeutic utility. Semin Urol Oncol 16 (1998) 118-123
6. Rasey J.S., Koh W.J., Evans M.L., Peterson L.M., Lewellen T.K., Graham M.M., et al. Quantifying regional hypoxia in human tumors with positron emission tomography of [18F]fluoromisonidazole: a pretherapy study of 37 patients. Int J Radiat Oncol Biol Phys 36 (1996) 417-428
7. O'Donoghue J.A., Zanzonico P., Pugachev A., Wen B., Smith-Jones P., Cai S., et al. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 61 (2005) 1493-1502
8. Nahum A.E., Movsas B., Horwitz E.M., Stobbe C.C., and Chapman J.D. Incorporating clinical measurements of hypoxia into tumor local control modeling of prostate cancer: implications for the alpha/beta ratio. Int J Radiat Oncol Biol Phys 57 (2003) 391-401
9. Kimbro K.S., and Simons J.W. Hypoxia-inducible factor-1 in human breast and prostate cancer. Endocr Relat Cancer 13 (2006) 739-749
10. Delongchamps N.B., Peyromaure M., and Dinh-Xuan A.T. Role of vascular endothelial growth factor in prostate cancer. Urology 68 (2006) 244-248
11. Effert P., Beniers A.J., Tamimi Y., Handt S., and Jakse G. Expression of glucose transporter 1 (Glut-1) in cell lines and clinical specimens from human prostate adenocarcinoma. Anticancer Res 24 (2004) 3057-3063
12. Tatum J.L., Kelloff G.J., Gillies R.J., Arbeit J.M., Brown J.M., Chao K.S., et al. Hypoxia: importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 82 (2006) 699-757
13. Said J. Biomarker discovery in urogenital cancer. Biomarkers 10 Suppl. 1 (2005) S83-S86
14. Moul J.W., Wu H., Sun L., McLeod D.G., Amling C., Lance R., et al. Epidemiology of radical prostatectomy for localized prostate cancer in the era of prostate-specific antigen: an overview of the Department of Defense Center for Prostate Disease Research national database. Surgery 132 (2002) 213-219
15. D'Amico A.V., Hui-Chen M., Renshaw A.A., Sussman B., Roehl K.A., and Catalona W.J. Identifying men diagnosed with clinically localized prostate cancer who are at high risk for death from prostate cancer. J Urol 176 (2006) S11-S15
16. Thompson I.M. Defining high risk prostate cancer-where do we set the bar? A translational science approach to risk stratification. J Urol 176 (2006) S21-S24 [discussion S25-S26]
17. Moul J.W. The evolving definition of advanced prostate cancer. Rev Urol 8 6 Suppl. (2004) S10-S17
18. Roach III M., Weinberg V., Nash M., Sandler H.M., McLaughlin P.W., Kattan M.W., et al. Defining high risk prostate cancer with risk groups and nomograms: implications for designing clinical trials. J Urol 176 (2006) S16-S20
19. 3) spatial resolution. Radiology 198 (1996) 795-805
20. Cookson M.S., Fleshner N.E., Soloway S.M., and Fair W.R. Correlation between Gleason score of needle biopsy and radical prostatectomy specimen: accuracy and clinical implications. J Urol 157 (1997) 559-562
21. Steinberg D.M., Sauvageot J., Piantadosi S., and Epstein J.I. Correlation of prostate needle biopsy and radical prostatectomy Gleason grade in academic and community settings. Am J Surg Pathol 21 (1997) 566-576
22. D'Amico A.V., Chen M.H., Catalona W.J., Sun L., Roehl K.A., and Moul J.W. Prostate cancer-specific mortality after radical prostatectomy or external beam radiation therapy in men with 1 or more high-risk factors. Cancer 110 (2007) 56-61
23. D'Amico F., Biancolella M., Margiotti K., Reichardt J.K., and Novelli G. Genomic biomarkers, androgen pathway and prostate cancer. Pharmacogenomics 8 (2007) 645-661
24. Hricak H. MR imaging and MR spectroscopic imaging in the pre-treatment evaluation of prostate cancer. Br J Radiol 78 Spec. No. 2 (2005) S103-S111
25. Dobosy J.R., Roberts J.L., Fu V.X., and Jarrard D.F. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia. J Urol 177 (2007) 822-831
26. Chun F.K., Karakiewicz P.I., Huland H., and Graefen M. Role of nomograms for prostate cancer in 2007. World J Urol 25 (2007) 131-142
27. Sun Y., and Oberley L.W. Redox regulation of transcriptional activators. Free Radic Biol Med 21 (1996) 335-348
28. Zhan M., and Han Z.C. Phosphatidylinositide 3-kinase/AKT in radiation responses. Histol Histopathol 19 (2004) 915-923
29. Rugo R.E., and Schiestl R.H. Increases in oxidative stress in the progeny of X-irradiated cells. Radiat Res 162 (2004) 416-425
30. Gilbert M., and Knox S. Influence of Bcl-2 overexpression on Na+/K(+)-ATPase pump activity: correlation with radiation-induced programmed cell death. J Cell Physiol 171 (1997) 299-304
31. Chresta C.M., Masters J.R., and Hickman J.A. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res 56 (1996) 1834-1841
32. Romashkova J.A., and Makarov S.S. NF-kappaB is a target of AKT in anti-apoptotic PDGF signalling. Nature 401 (1999) 86-90
33. Boddy J.L., Fox S.B., Han C., Campo L., Turley H., Kanga S., et al. The androgen receptor is significantly associated with vascular endothelial growth factor and hypoxia sensing via hypoxia-inducible factors HIF-1a, HIF-2a, and the prolyl hydroxylases in human prostate cancer. Clin Cancer Res 11 (2005) 7658-7663
34. Zhong H., De Marzo A.M., Laughner E., Lim M., Hilton D.A., Zagzag D., et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 59 (1999) 5830-5835
35. Lekas A., Lazaris A.C., Deliveliotis C., Chrisofos M., Zoubouli C., Lapas D., et al. The expression of hypoxia-inducible factor-1alpha (HIF-1alpha) and angiogenesis markers in hyperplastic and malignant prostate tissue. Anticancer Res 26 (2006) 2989-2993
36. Chun Y.S., Lee K.H., Choi E., Bae S.Y., Yeo E.J., Huang L.E., et al. Phorbol ester stimulates the nonhypoxic induction of a novel hypoxia-inducible factor 1alpha isoform: implications for tumor promotion. Cancer Res 63 (2003) 8700-8707
37. Eliceiri B.P., Paul R., Schwartzberg P.L., Hood J.D., Leng J., and Cheresh D.A. Selective requirement for Src kinases during VEGF-induced angiogenesis and vascular permeability. Mol Cell 4 (1999) 915-924
38. Jiang B.H., Jiang G., Zheng J.Z., Lu Z., Hunter T., and Vogt P.K. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell Growth Differ 12 (2001) 363-369
39. Jiang B.H., Rue E., Wang G.L., Roe R., and Semenza G.L. Dimerization, DNA binding, and transactivation properties of hypoxia-inducible factor 1. J Biol Chem 271 (1996) 17771-17778
40. Jiang B.H., Zheng J.Z., Leung S.W., Roe R., and Semenza G.L. Transactivation and inhibitory domains of hypoxia-inducible factor 1alpha. Modulation of transcriptional activity by oxygen tension. J Biol Chem 272 (1997) 19253-19260
41. Alvarez-Tejado M., Naranjo-Suarez S., Jimenez C., Carrera A.C., Landazuri M.O., and del Peso L. Hypoxia induces the activation of the phosphatidylinositol 3-kinase/Akt cell survival pathway in PC12 cells: protective role in apoptosis. J Biol Chem 276 (2001) 22368-22374
42. Zhong X.S., Zheng J.Z., Reed E., and Jiang B.H. SU5416 inhibited VEGF and HIF-1alpha expression through the PI3K/AKT/p70S6K1 signaling pathway. Biochem Biophys Res Commun 324 (2004) 471-480
43. Ellis L.M., Staley C.A., Liu W., Fleming R.Y., Parikh N.U., Bucana C.D., et al. Down-regulation of vascular endothelial growth factor in a human colon carcinoma cell line transfected with an antisense expression vector specific for c-src. J Biol Chem 273 (1998) 1052-1057
44. Namiki A., Brogi E., Kearney M., Kim E.A., Wu T., Couffinhal T., et al. Hypoxia induces vascular endothelial growth factor in cultured human endothelial cells. J Biol Chem 270 (1995) 31189-31195
45. Thompson I.M., and Optenberg S.A. An overview cost-utility analysis of prostate cancer screening. Oncology (Huntington) 9 (1995) 141-145
46. Zundel W., Schindler C., Haas-Kogan D., Koong A., Kaper F., Chen E., et al. Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14 (2000) 391-396
47. An W.G., Kanekal M., Simon M.C., Maltepe E., Blagosklonny M.V., and Neckers L.M. Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. Nature 392 (1998) 405-408
48. Ravi R., Mookerjee B., Bhujwalla Z.M., Sutter C.H., Artemov D., Zeng Q., et al. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev 14 (2000) 34-44
49. Storz P. Reactive oxygen species in tumor progression. Front Biosci 10 (2005) 1881-1896
50. Shen H.M., and Liu Z.G. JNK signaling pathway is a key modulator in cell death mediated by reactive oxygen and nitrogen species. Free Radic Biol Med 40 (2006) 928-939
51. Shackelford R.E., Kaufmann W.K., and Paules R.S. Oxidative stress and cell cycle checkpoint function. Free Radic Biol Med 28 (2000) 1387-1404
52. Muzandu K., Shaban Z., Ishizuka M., Kazusaka A., and Fujita S. Nitric oxide enhances catechol estrogen-induced oxidative stress in LNCaP cells. Free Radic Res 39 (2005) 389-398
53. Kaelin Jr. W.G. ROS: really involved in oxygen sensing. Cell Metab 1 (2005) 357-358
54. Gao N., Jiang B.H., Leonard S.S., Corum L., Zhang Z., Roberts J.R., et al. p38 Signaling-mediated hypoxia-inducible factor 1alpha and vascular endothelial growth factor induction by Cr(VI) in DU145 human prostate carcinoma cells. J Biol Chem 277 (2002) 45041-45048
55. Pelicano H., Martin D.S., Xu R.H., and Huang P. Glycolysis inhibition for anticancer treatment. Oncogene 25 (2006) 4633-4646
56. Brandon M., Baldi P., and Wallace D.C. Mitochondrial mutations in cancer. Oncogene 25 (2006) 4647-4662
57. King A., Selak M.A., and Gottlieb E. Succinate dehydrogenase and fumarate hydratase: linking mitochondrial dysfunction and cancer. Oncogene 25 (2006) 4675-4682
58. Moll U.M., Marchenko N., and Zhang X.K. p53 and Nur77/TR3 - transcription factors that directly target mitochondria for cell death induction. Oncogene 25 (2006) 4725-4743
59. Kroemer G. Mitochondria in cancer. Oncogene 25 (2006) 4630-4632
60. Asatiani E., Huang W.X., Wang A., Rodriguez Ortner E., Cavalli L.R., Haddad B.R., et al. Deletion, methylation, and expression of the NKX3. 1 suppressor gene in primary human prostate cancer. Cancer Res 65 (2005) 1164-1173
61. Jeronimo C., Varzim G., Henrique R., Oliveira J., Bento M.J., Silva C., et al. I105V polymorphism and promoter methylation of the GSTP1 gene in prostate adenocarcinoma. Cancer Epidemiol Biomarkers Prev 11 (2002) 445-450
62. Trzeciak A.R., Nyaga S.G., Jaruga P., Lohani A., Dizdaroglu M., and Evans M.K. Cellular repair of oxidatively induced DNA base lesions is defective in prostate cancer cell lines, PC-3 and DU-145. Carcinogenesis 25 (2004) 1359-1370
63. Suzuki Y., Kondo Y., Himeno S., Nemoto K., Akimoto M., and Imura N. Role of antioxidant systems in human androgen-independent prostate cancer cells. Prostate 43 (2000) 144-149
64. Tomlins S.A., Mehra R., Rhodes D.R., Cao X., Wang L., Dhanasekaran S.M., et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 39 (2007) 41-51
65. Oettgen P. Regulation of vascular inflammation and remodeling by ETS factors. Circ Res 99 (2006) 1159-1166
66. Aprelikova O., Wood M., Tackett S., Chandramouli G.V., and Barrett J.C. Role of ETS transcription factors in the hypoxia-inducible factor-2 target gene selection. Cancer Res 66 (2006) 5641-5647
67. Huang X., Brown C., Ni W., Maynard E., Rigby A.C., and Oettgen P. Critical role for the Ets transcription factor ELF-1 in the development of tumor angiogenesis. Blood 107 (2006) 3153-3160
68. Carroll V.A., and Ashcroft M. Role of hypoxia-inducible factor (HIF)-1alpha versus HIF-2alpha in the regulation of HIF target genes in response to hypoxia, insulin-like growth factor-I, or loss of von Hippel-Lindau function, implications for targeting the HIF pathway. Cancer Res 66 (2006) 6264-6270
69. Hu C.J., Wang L.Y., Chodosh L.A., Keith B., and Simon M.C. Differential roles of hypoxia-inducible factor 1alpha (HIF-1alpha) and HIF-2alpha in hypoxic gene regulation. Mol Cell Biol 23 (2003) 9361-9374
70. Ripple M.O., Henry W.F., Rago R.P., and Wilding G. Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J Natl Cancer Inst 89 (1997) 40-48
71. Meurette O., Lefeuvre-Orfila L., Rebillard A., Lagadic-Gossmann D., and Dimanche-Boitrel M.T. Role of intracellular glutathione in cell sensitivity to the apoptosis induced by tumor necrosis factor {alpha}-related apoptosis-inducing ligand/anticancer drug combinations. Clin Cancer Res 11 (2005) 3075-3083
72. Chan N., Milosevic M., and Bristow R.G. Tumor hypoxia, DNA repair and prostate cancer progression, new targets and new therapies. Future Oncol 3 (2007) 329-341
73. Delahoussaye Y.M., Hay M.P., Pruijn F.B., Denny W.A., and Brown J.M. Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting. Biochem Pharmacol 65 (2003) 1807-1815
74. Kelley M.R., Cheng L., Foster R., Tritt R., Jiang J., Broshears J., et al. Elevated and altered expression of the multifunctional DNA base excision repair and redox enzyme Ape1/ref-1 in prostate cancer. Clin Cancer Res 7 (2001) 824-830
75. Bindra R.S., and Glazer P.M. Co-repression of mismatch repair gene expression by hypoxia in cancer cells: role of the Myc/Max network. Cancer Lett 252 (2007) 93-103
76. Norris A.M., Woodruff R.D., D'Agostino Jr. R.B., Clodfelter J.E., and Scarpinato K.D. Elevated levels of the mismatch repair protein PMS2 are associated with prostate cancer. Prostate 67 (2007) 214-225
77. Fan R., Kumaravel T.S., Jalali F., Marrano P., Squire J.A., and Bristow R.G. Defective DNA strand break repair after DNA damage in prostate cancer cells: implications for genetic instability and prostate cancer progression. Cancer Res 64 (2004) 8526-8533
78. Bindra R.S., and Glazer P.M. Repression of RAD51 gene expression by E2F4/p130 complexes in hypoxia. Oncogene 26 (2007) 2048-2057
79. Guise C.P., Wang A.T., Theil A., Bridewell D.J., Wilson W.R., and Patterson A.V. Identification of human reductases that activate the dinitrobenzamide mustard prodrug PR-104A: a role for NADPH:cytochrome P450 oxidoreductase under hypoxia. Biochem Pharmacol 74 (2007) 810-820
80. Meng A.X., Jalali F., Cuddihy A., Chan N., Bindra R.S., Glazer P.M., et al. Hypoxia down-regulates DNA double strand break repair gene expression in prostate cancer cells. Radiother Oncol 76 (2005) 168-176
81. To K.K., Sedelnikova O.A., Samons M., Bonner W.M., and Huang L.E. The phosphorylation status of PAS-B distinguishes HIF-1alpha from HIF-2alpha in NBS1 repression. EMBO J 25 (2006) 4784-4794
82. Brown J.M., and Attardi L.D. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 5 (2005) 231-237
83. Weinmann M., Jendrossek V., Guner D., Goecke B., and Belka C. Cyclic exposure to hypoxia and reoxygenation selects for tumor cells with defects in mitochondrial apoptotic pathways. FASEB J 18 (2004) 1906-1908
84. Aho T.L., Sandholm J., Peltola K.J., Mankonen H.P., Lilly M., and Koskinen P.J. Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett 571 (2004) 43-49
85. Xie Y., Xu K., Dai B., Guo Z., Jiang T., Chen H., et al. The 44 kDa Pim-1 kinase directly interacts with tyrosine kinase Etk/BMX and protects human prostate cancer cells from apoptosis induced by chemotherapeutic drugs. Oncogene 25 (2006) 70-78
86. Graeber T.G., Osmanian C., Jacks T., Housman D.E., Koch C.J., Lowe S.W., et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 379 (1996) 88-91
87. Revelos K., Petraki C., Gregorakis A., Scorilas A., Papanastasiou P., and Koutsilieris M. Immunohistochemical expression of Bcl2 is an independent predictor of time-to-biochemical failure in patients with clinically localized prostate cancer following radical prostatectomy. Anticancer Res 25 (2005) 3123-3133
88. Rohn T.A., Wagenknecht B., Roth W., Naumann U., Gulbins E., Krammer P.H., et al. CCNU-dependent potentiation of TRAIL/Apo2L-induced apoptosis in human glioma cells is p53-independent but may involve enhanced cytochrome c release. Oncogene 20 (2001) 4128-4137
89. Huang A., Gandour-Edwards R., Rosenthal S.A., Siders D.B., Deitch A.D., and White R.W. p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy. Urology 51 (1998) 346-351
90. Scherr D.S., Vaughan Jr. E.D., Wei J., Chung M., Felsen D., Allbright R., et al. BCL-2 and p53 expression in clinically localized prostate cancer predicts response to external beam radiotherapy. J Urol 162 (1999) 12-16 [discussion 16-17]
91. Szostak M.J., and Kyprianou N. Radiation-induced apoptosis: predictive and therapeutic significance in radiotherapy of prostate cancer (review). Oncol Rep 7 (2000) 699-706
92. Zhivotovsky B., Joseph B., and Orrenius S. Tumor radiosensitivity and apoptosis. Exp Cell Res 248 (1999) 10-17
93. Wang G., Reed E., and Li Q.Q. Apoptosis in prostate cancer: progressive and therapeutic implications (Review). Int J Mol Med 14 (2004) 23-34
94. Mouraviev V., Li L., Tahir S.A., Yang G., Timme T.M., Goltsov A., et al. The role of caveolin-1 in androgen insensitive prostate cancer. J Urol 168 (2002) 1589-1596
95. Datta S.R., Dudek H., Tao X., Masters S., Fu H., Gotoh Y., et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91 (1997) 231-241
96. Yamaguchi H., and Wang H.G. The protein kinase PKB/Akt regulates cell survival and apoptosis by inhibiting Bax conformational change. Oncogene 20 (2001) 7779-7786
97. Sastry K.S., Smith A.J., Karpova Y., Datta S.R., and Kulik G. Diverse antiapoptotic signaling pathways activated by vasoactive intestinal polypeptide, epidermal growth factor, and phosphatidylinositol 3-kinase in prostate cancer cells converge on BAD. J Biol Chem 281 (2006) 20891-20901
98. Wendt J., von Haefen C., Hemmati P., Belka C., Dorken B., and Daniel P.T. TRAIL sensitizes for ionizing irradiation-induced apoptosis through an entirely Bax-dependent mitochondrial cell death pathway. Oncogene 24 (2005) 4052-4064
99. Cardone M.H., Roy N., Stennicke H.R., Salvesen G.S., Franke T.F., Stanbridge E., et al. Regulation of cell death protease caspase-9 by phosphorylation. Science 282 (1998) 1318-1321
100. Wilson B.E., Mochon E., and Boxer L.M. Induction of bcl-2 expression by phosphorylated CREB proteins during B-cell activation and rescue from apoptosis. Mol Cell Biol 16 (1996) 5546-5556
101. Chrivia J.C., Kwok R.P., Lamb N., Hagiwara M., Montminy M.R., and Goodman R.H. Phosphorylated CREB binds specifically to the nuclear protein CBP. Nature 365 (1993) 855-859
102. Unruh A., Ressel A., Mohamed H.G., Johnson R.S., Nadrowitz R., Richter E., et al. The hypoxia-inducible factor-1 alpha is a negative factor for tumor therapy. Oncogene 22 (2003) 3213-3220
103. Dong Z., Wang J.Z., Yu F., and Venkatachalam M.A. Apoptosis-resistance of hypoxic cells: multiple factors involved and a role for IAP-2. Am J Pathol 163 (2003) 663-671
104. Rothermund C.A., Gopalakrishnan V.K., Eudy J.D., and Vishwanatha J.K. Casodex treatment induces hypoxia-related gene expression in the LNCaP prostate cancer progression model. BMC Urol 5 (2005) 5
105. Park S.Y., Kim Y.J., Gao A.C., Mohler J.L., Onate S.A., Hidalgo A.A., et al. Hypoxia increases androgen receptor activity in prostate cancer cells. Cancer Res 66 (2006) 5121-5129
106. Milosevic M., Chung P., Parker C., Bristow R., Toi A., Panzarella T., et al. Androgen withdrawal in patients reduces prostate cancer hypoxia: implications for disease progression and radiation response. Cancer Res 67 (2007) 6022-6025
107. Aslan G., Cimen S., Yorukoglu K., Tuna B., Sonmez D., Mungan U., et al. Vascular endothelial growth factor expression in untreated and androgen-deprived patients with prostate cancer. Pathol Res Pract 201 (2005) 593-598
108. Bakin R.E., Gioeli D., Sikes R.A., Bissonette E.A., and Weber M.J. Constitutive activation of the Ras/mitogen-activated protein kinase signaling pathway promotes androgen hypersensitivity in LNCaP prostate cancer cells. Cancer Res 63 (2003) 1981-1989
109. Mabjeesh N.J., Willard M.T., Frederickson C.E., Zhong H., and Simons J.W. Androgens stimulate hypoxia-inducible factor 1 activation via autocrine loop of tyrosine kinase receptor/phosphatidylinositol 3′-kinase/protein kinase B in prostate cancer cells. Clin Cancer Res 9 (2003) 2416-2425
110. Feldman B.J., and Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer 1 (2001) 34-45
111. Fujimoto N., Mizokami A., Harada S., and Matsumoto T. Different expression of androgen receptor coactivators in human prostate. Urology 58 (2001) 289-294
112. Gregory C.W., He B., Johnson R.T., Ford O.H., Mohler J.L., French F.S., et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61 (2001) 4315-4319
113. Aarnisalo P., Palvimo J.J., and Janne O.A. CREB-binding protein in androgen receptor-mediated signaling. Proc Natl Acad Sci USA 95 (1998) 2122-2127
114. Ruas J.L., Poellinger L., and Pereira T. Role of CBP in regulating HIF-1-mediated activation of transcription. J Cell Sci 118 (2005) 301-311
115. Culig Z., and Bartsch G. Androgen axis in prostate cancer. J Cell Biochem 99 (2006) 373-381
116. Pfeil K., Eder I.E., Putz T., Ramoner R., Culig Z., Ueberall F., et al. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells. Prostate 58 (2004) 259-268
117. Hermans K.G., van Alewijk D.C., Veltman J.A., van Weerden W., van Kessel A.G., and Trapman J. Loss of a small region around the PTEN locus is a major chromosome 10 alteration in prostate cancer xenografts and cell lines. Genes Chromosomes Cancer 39 (2004) 171-184
118. Li J., Yen C., Liaw D., Podsypanina K., Bose S., Wang S.I., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275 (1997) 1943-1947
119. Chen T., Wang L.H., and Farrar W.L. Interleukin 6 activates androgen receptor-mediated gene expression through a signal transducer and activator of transcription 3-dependent pathway in LNCaP prostate cancer cells. Cancer Res 60 (2000) 2132-2135
120. Niu G., Wright K.L., Huang M., Song L., Haura E., Turkson J., et al. Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesis. Oncogene 21 (2002) 2000-2008
121. Wei D., Le X., Zheng L., Wang L., Frey J.A., Gao A.C., et al. Stat3 activation regulates the expression of vascular endothelial growth factor and human pancreatic cancer angiogenesis and metastasis. Oncogene 22 (2003) 319-329
122. Culig Z., Hobisch A., Cronauer M.V., Radmayr C., Trapman J., Hittmair A., et al. Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor, and epidermal growth factor. Cancer Res 54 (1994) 5474-5478
123. Koivisto P.A., and Rantala I. Amplification of the androgen receptor gene is associated with P53 mutation in hormone-refractory recurrent prostate cancer. J Pathol 187 (1999) 237-241
124. Cochrane D.R., Wang Z., Muramaki M., Gleave M.E., and Nelson C.C. Differential regulation of clusterin and its isoforms by androgens in prostate cells. J Biol Chem 282 (2007) 2278-2287
125. Nakamura E., Abreu-e-Lima P., Awakura Y., Inoue T., Kamoto T., Ogawa O., et al. Clusterin is a secreted marker for a hypoxia-inducible factor-independent function of the von Hippel-Lindau tumor suppressor protein. Am J Pathol 168 (2006) 574-584
126. Horii K., Suzuki Y., Kondo Y., Akimoto M., Nishimura T., Yamabe Y., et al. Androgen-dependent gene expression of prostate-specific antigen is enhanced synergistically by hypoxia in human prostate cancer cells. Mol Cancer Res 5 (2007) 383-391
127. Kim O., Jiang T., Xie Y., Guo Z., Chen H., and Qiu Y. Synergism of cytoplasmic kinases in IL6-induced ligand-independent activation of androgen receptor in prostate cancer cells. Oncogene 23 (2004) 1838-1844
128. Liang H., Hittelman W., and Nagarajan L. Ubiquitous expression and cell cycle regulation of the protein kinase PIM-1. Arch Biochem Biophys 330 (1996) 259-265
129. Thompson J., Peltola K.J., Koskinen P.J., Janne O.A., and Palvimo J.J. Attenuation of androgen receptor-dependent transcription by the serine/threonine kinase Pim-1. Lab Invest 83 (2003) 1301-1309
130. Valdman A., Fang X., Pang S.T., Ekman P., and Egevad L. Pim-1 expression in prostatic intraepithelial neoplasia and human prostate cancer. Prostate 60 (2004) 367-371
131. Dhanasekaran S.M., Barrette T.R., Ghosh D., Shah R., Varambally S., Kurachi K., et al. Delineation of prognostic biomarkers in prostate cancer. Nature 412 (2001) 822-826
132. Fujita H., Koshida K., Keller E.T., Takahashi Y., Yoshimito T., Namiki M., et al. Cyclooxygenase-2 promotes prostate cancer progression. Prostate 53 (2002) 232-240
133. Pruthi R.S., and Wallen E.M. Cyclooxygenase-2: a therapeutic target for prostate cancer. Clin Genitourin Cancer 4 (2005) 203-211
134. Liu X.H., Kirschenbaum A., Yu K., Yao S., and Levine A.C. Cyclooxygenase-2 suppresses hypoxia-induced apoptosis via a combination of direct and indirect inhibition of p53 activity in a human prostate cancer cell line. J Biol Chem 280 (2005) 3817-3823
135. Sramkoski R.M., Pretlow II T.G., Giaconia J.M., Pretlow T.P., Schwartz S., Sy M.S., et al. A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 35 (1999) 403-409
136. Sooriakumaran P., Langley S.E., Laing R.W., and Coley H.M. COX-2 inhibition: a possible role in the management of prostate cancer?. J Chemother 19 (2007) 21-32
137. Miyamoto H., Altuwaijri S., Cai Y., Messing E.M., and Chang C. Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer. Mol Carcinogen 44 (2005) 1-10
138. Shain K.H., and Dalton W.S. Cell adhesion is a key determinant in de novo multidrug resistance (MDR): new targets for the prevention of acquired MDR. Mol Cancer Ther 1 (2001) 69-78
139. Fischer O.M., Hart S., Gschwind A., Prenzel N., and Ullrich A. Oxidative and osmotic stress signaling in tumor cells is mediated by ADAM proteases and heparin-binding epidermal growth factor. Mol Cell Biol 24 (2004) 5172-5183
140. Sung S.Y., Kubo H., Shigemura K., Arnold R.S., Logani S., Wang R., et al. Oxidative stress induces ADAM9 protein expression in human prostate cancer cells. Cancer Res 66 (2006) 9519-9526
141. Bhangal G., Halford S., Wang J., Roylance R., Shah R., and Waxman J. Expression of the multidrug resistance gene in human prostate cancer. Urol Oncol 5 (2000) 118-121
142. Izbicka E., Dalton W.S., Troyer D., and Von Hoff D.D. Expression of two multidrug resistance genes in human prostatic carcinomas. J Natl Cancer Inst 90 (1998) 166-167
143. Fojo A.T., Ueda K., Slamon D.J., Poplack D.G., Gottesman M.M., and Pastan I. Expression of a multidrug-resistance gene in human tumors and tissues. Proc Natl Acad Sci USA 84 (1987) 265-269
144. Theyer G., Schirmbock M., Thalhammer T., Sherwood E.R., Baumgartner G., and Hamilton G. Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines. J Urol 150 (1993) 1544-1547
145. Lee G., and Piquette-Miller M. Cytokines alter the expression and activity of the multidrug resistance transporters in human hepatoma cell lines; analysis using RT-PCR and cDNA microarrays. J Pharm Sci 92 (2003) 2152-2163
146. Yang J.M., Sullivan G.F., and Hait W.N. Regulation of the function of P-glycoprotein by epidermal growth factor through phospholipase C. Biochem Pharmacol 53 (1997) 1597-1604
147. Wartenberg M., Gronczynska S., Bekhite M.M., Saric T., Niedermeier W., Hescheler J., et al. Regulation of the multidrug resistance transporter P-glycoprotein in multicellular prostate tumor spheroids by hyperthermia and reactive oxygen species. Int J Cancer 113 (2005) 229-240
148. Wartenberg M., Hoffmann E., Schwindt H., Grunheck F., Petros J., Arnold J.R., et al. Reactive oxygen species-linked regulation of the multidrug resistance transporter P-glycoprotein in Nox-1 overexpressing prostate tumor spheroids. FEBS Lett 579 (2005) 4541-4549
149. Thews O., Gassner B., Kelleher D.K., Schwerdt G., and Gekle M. Impact of extracellular acidity on the activity of P-glycoprotein and the cytotoxicity of chemotherapeutic drugs. Neoplasia 8 (2006) 143-152
150. Enokida H., Shiina H., Igawa M., Ogishima T., Kawakami T., Bassett W.W., et al. CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer. Cancer Res 64 (2004) 5956-5962
151. Zalcberg J., Hu X.F., Slater A., Parisot J., El-Osta S., Kantharidis P., et al. MRP1 not MDR1 gene expression is the predominant mechanism of acquired multidrug resistance in two prostate carcinoma cell lines. Prostate Cancer Prostatic Dis 3 (2000) 66-75
152. Sullivan G.F., Amenta P.S., Villanueva J.D., Alvarez C.J., Yang J.M., and Hait W.N. The expression of drug resistance gene products during the progression of human prostate cancer. Clin Cancer Res 4 (1998) 1393-1403
153. Lee Jr. J.T., Steelman L.S., and McCubrey J.A. Phosphatidylinositol 3′-kinase activation leads to multidrug resistance protein-1 expression and subsequent chemoresistance in advanced prostate cancer cells. Cancer Res 64 (2004) 8397-8404
154. Vlietstra R.J., van Alewijk D.C., Hermans K.G., van Steenbrugge G.J., and Trapman J. Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 58 (1998) 2720-2723
155. Murillo H., Huang H., Schmidt L.J., Smith D.I., and Tindall D.J. Role of PI3K signaling in survival and progression of LNCaP prostate cancer cells to the androgen refractory state. Endocrinology 142 (2001) 4795-4805
156. Teicher B.A. Hypoxia and drug resistance. Cancer Metastasis Rev 13 (1994) 139-168
157. Escuin D., Kline E.R., and Giannakakou P. Both microtubule-stabilizing and microtubule-destabilizing drugs inhibit hypoxia-inducible factor-1alpha accumulation and activity by disrupting microtubule function. Cancer Res 65 (2005) 9021-9028
158. Liu L., Ning X., Sun L., Shi Y., Han S., Guo C., et al. Involvement of MGr1-Ag/37LRP in the vincristine-induced HIF-1 expression in gastric cancer cells. Mol Cell Biochem 303 (2007) 151-160
159. Zeng L., Kizaka-Kondoh S., Itasaka S., Xie X., Inoue M., Tanimoto K., et al. Hypoxia inducible factor-1 influences sensitivity to paclitaxel of human lung cancer cell lines under normoxic conditions. Cancer Sci 98 (2007) 1394-1401
160. Patenaude A., Deschesnes R.G., Rousseau J.L., Petitclerc E., Lacroix J., Cote M.F., et al. New soft alkylating agents with enhanced cytotoxicity against cancer cells resistant to chemotherapeutics and hypoxia. Cancer Res 67 (2007) 2306-2316
161. Skvortsova I., Skvortsov S., Haidenberger A., Devries A., Nevinny-Stickel M., Saurer M., et al. Effects of paclitaxel and docetaxel on EGFR-expressing human carcinoma cells under normoxic versus hypoxic conditions in vitro. J Chemother 16 (2004) 372-380
162. Thews O., Gassner B., Kelleher D.K., Schwerdt G., and Gekle M. Impact of hypoxic and acidic extracellular conditions on cytotoxicity of chemotherapeutic drugs. Adv Exp Med Biol 599 (2007) 155-161
163. Tester W., Ackler J., Tijani L., and Leighton J. Phase I/II study of
164. Hess-Wilson J.K., Daly H.K., Zagorski W.A., Montville C.P., and Knudsen K.E. Mitogenic action of the androgen receptor sensitizes prostate cancer cells to taxane-based cytotoxic insult. Cancer Res 66 (2006) 11998-12008
165. Comstock C.E., and Knudsen K.E. The complex role of AR signaling after cytotoxic insult: implications for cell-cycle-based chemotherapeutics. Cell Cycle 6 (2007) 1307-1313
166. Mangar S.A., Huddart R.A., Parker C.C., Dearnaley D.P., Khoo V.S., and Horwich A. Technological advances in radiotherapy for the treatment of localised prostate cancer. Eur J Cancer 41 (2005) 908-921
167. Potters L., Torre T., Fearn P.A., Leibel S.A., and Kattan M.W. Potency after permanent prostate brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 50 (2001) 1235-1242
168. Machtens S., Baumann R., Hagemann J., Warszawski A., Meyer A., Karstens J.H., et al. Long-term results of interstitial brachytherapy (LDR-Brachytherapy) in the treatment of patients with prostate cancer. World J Urol 24 (2006) 289-295
169. Zelefsky M.J., Chan H., Hunt M., Yamada Y., Shippy A.M., and Amols H. Long-term outcome of high dose intensity modulated radiation therapy for patients with clinically localized prostate cancer. J Urol 176 (2006) 1415-1419
170. Skov K., Adomat H., Bowden M., Dragowska W., Gleave M., Koch C.J., et al. Hypoxia in the androgen-dependent Shionogi model for prostate cancer at three stages. Radiat Res 162 (2004) 547-553
171. McNab J.A., Yung A.C., and Kozlowski P. Tissue oxygen tension measurements in the Shionogi model of prostate cancer using 19F MRS and MRI. Magma 17 (2004) 288-295
172. Hall E.J., Bedford J.S., and Oliver R. Extreme hypoxia; its effect on the survival of mammalian cells irradiated at high and low dose-rates. Br J Radiol 39 (1966) 302-307
173. Zolzer F., and Streffer C. Increased radiosensitivity with chronic hypoxia in four human tumor cell lines. Int J Radiat Oncol Biol Phys 54 (2002) 910-920
174. McBride W.H., Iwamoto K.S., Syljuasen R., Pervan M., and Pajonk F. The role of the ubiquitin/proteasome system in cellular responses to radiation. Oncogene 22 (2003) 5755-5773
175. Pervan M., Iwamoto K.S., and McBride W.H. Proteasome structures affected by ionizing radiation. Mol Cancer Res 3 (2005) 381-390
176. Rakozy C., Grignon D.J., Li Y., Gheiler E., Gururajanna B., Pontes J.E., et al. p53 gene alterations in prostate cancer after radiation failure and their association with clinical outcome: a molecular and immunohistochemical analysis. Pathol Res Pract 195 (1999) 129-135
177. Marples B., Greco O., Joiner M.C., and Scott S.D. Radiogenetic therapy: strategies to overcome tumor resistance. Curr Pharm Des 9 (2003) 2105-2112
178. Lehmann B.D., McCubrey J.A., Jefferson H.S., Paine M.S., Chappell W.H., and Terrian D.M. A dominant role for p53-dependent cellular senescence in radiosensitization of human prostate cancer cells. Cell Cycle 6 (2007) 595-605
179. Pollycove M., and Feinendegen L.E. Radiation-induced versus endogenous DNA damage: possible effect of inducible protective responses in mitigating endogenous damage. Hum Exp Toxicol 22 (2003) 290-306 [discussion 307, 315-297, 319-22]
180. Dent P., Yacoub A., Fisher P.B., Hagan M.P., and Grant S. MAPK pathways in radiation responses. Oncogene 22 (2003) 5885-5896
181. Chadderton N., Cowen R.L., Sheppard F.C., Robinson S., Greco O., Scott S.D., et al. Dual responsive promoters to target therapeutic gene expression to radiation-resistant hypoxic tumor cells. Int J Radiat Oncol Biol Phys 62 (2005) 213-222
182. Mayo M.W., and Baldwin A.S. The transcription factor NF-kappaB: control of oncogenesis and cancer therapy resistance. Biochim Biophys Acta 1470 (2000) M55-M62
183. Chen C.D., and Sawyers C.L. NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol 22 (2002) 2862-2870
184. Wang C.Y., Guttridge D.C., Mayo M.W., and Baldwin Jr. A.S. NF-kappaB induces expression of the Bcl-2 homologue A1/Bfl-1 to preferentially suppress chemotherapy-induced apoptosis. Mol Cell Biol 19 (1999) 5923-5929
185. Wang C.Y., Mayo M.W., Korneluk R.G., Goeddel D.V., and Baldwin Jr. A.S. NF-kappaB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 281 (1998) 1680-1683
186. Bharti A.C., and Aggarwal B.B. Nuclear factor-kappa B and cancer: its role in prevention and therapy. Biochem Pharmacol 64 (2002) 883-888
187. McKenna W.G., and Muschel R.J. Targeting tumor cells by enhancing radiation sensitivity. Genes Chromosomes Cancer 38 (2003) 330-338
188. McKenna W.G., Muschel R.J., Gupta A.K., Hahn S.M., and Bernhard E.J. The RAS signal transduction pathway and its role in radiation sensitivity. Oncogene 22 (2003) 5866-5875
189. Hamasu T., Inanami O., Tsujitani M., Yokoyama K., Takahashi E., Kashiwakura I., et al. Post-irradiation hypoxic incubation of X-irradiated MOLT-4 cells reduces apoptotic cell death by changing the intracellular redox state and modulating SAPK/JNK pathways. Apoptosis 10 (2005) 557-567
190. Tolcher A.W., Chi K., Kuhn J., Gleave M., Patnaik A., Takimoto C., et al. A phase II, pharmacokinetic, and biological correlative study of oblimersen sodium and docetaxel in patients with hormone-refractory prostate cancer. Clin Cancer Res 11 (2005) 3854-3861
191. Martinive P., Defresne F., Bouzin C., Saliez J., Lair F., Gregoire V., et al. Preconditioning of the tumor vasculature and tumor cells by intermittent hypoxia: implications for anticancer therapies. Cancer Res 66 (2006) 11736-11744
192. Moeller B.J., and Dewhirst M.W. Raising the bar: how HIF-1 helps determine tumor radiosensitivity. Cell Cycle 3 (2004) 1107-1110
193. Callapina M., Zhou J., Schmid T., Kohl R., and Brune B. NO restores HIF-1alpha hydroxylation during hypoxia: role of reactive oxygen species. Free Radic Biol Med 39 (2005) 925-936
194. Bell E.N., Tse M.Y., Frederiksen L.J., Gardhouse A., Pang S.C., Graham C.H., et al. Atrial natriuretic peptide attenuates hypoxia induced chemoresistance in prostate cancer cells. J Urol 177 (2007) 751-756
195. Frederiksen L.J., Sullivan R., Maxwell L.R., Macdonald-Goodfellow S.K., Adams M.A., Bennett B.M., et al. Chemosensitization of cancer in vitro and in vivo by nitric oxide signaling. Clin Cancer Res 13 (2007) 2199-2206
196. Koritzinsky M., Seigneuric R., Magagnin M.G., van den Beucken T., Lambin P., and Wouters B.G. The hypoxic proteome is influenced by gene-specific changes in mRNA translation. Radiother Oncol 76 (2005) 177-186
197. Anderson P., and Kedersha N. RNA granules. J Cell Biol 172 (2006) 803-808
198. Kedersha N., and Anderson P. Stress granules: sites of mRNA triage that regulate mRNA stability and translatability. Biochem Soc Trans 30 (2002) 963-969
199. Kedersha N., Stoecklin G., Ayodele M., Yacono P., Lykke-Andersen J., Fritzler M.J., et al. Stress granules and processing bodies are dynamically linked sites of mRNP remodeling. J Cell Biol 169 (2005) 871-884
200. Moeller B.J., Cao Y., Li C.Y., and Dewhirst M.W. Radiation activates HIF-1 to regulate vascular radiosensitivity in tumors: role of reoxygenation, free radicals, and stress granules. Cancer Cell 5 (2004) 429-441
201. Jensen R.L., Ragel B.T., Whang K., and Gillespie D. Inhibition of hypoxia inducible factor-1alpha (HIF-1alpha) decreases vascular endothelial growth factor (VEGF) secretion and tumor growth in malignant gliomas. J Neurooncol 78 (2006) 233-247
202. Mizuno T., Nagao M., Yamada Y., Narikiyo M., Ueno M., Miyagishi M., et al. Small interfering RNA expression vector targeting hypoxia-inducible factor 1 alpha inhibits tumor growth in hepatobiliary and pancreatic cancers. Cancer Gene Ther 13 (2006) 131-140
203. Castedo M., Perfettini J.L., Roumier T., Andreau K., Medema R., and Kroemer G. Cell death by mitotic catastrophe: a molecular definition. Oncogene 23 (2004) 2825-2837
204. Magnon C., Opolon P., Ricard M., Connault E., Ardouin P., Galaup A., et al. Radiation and inhibition of angiogenesis by canstatin synergize to induce HIF-1alpha-mediated tumor apoptotic switch. J Clin Invest 117 (2007) 1844-1855